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INTRODUCTION
                 
                  Bone metastases often present as the first evidence of disseminated disease.  
The incidence of bone metastases varies significantly depending on the primary site, with 
breast and prostate cancer accounting for up to 70% of patients with metastatic disease .
                  Even though the ultimate prognosis is poor, a proportion of the patients may 
survive for several months or even years and will require active treatment because of 
symptoms related to their  bone metastases.  Pain,  pathologic fractures,  hypercalcemia, 
neurologic  deficits,  and  immobility  decrease  the  quality  of  remaining  life  for  these 
patients.  Associated  depression  and  anxiety  may  further  compromise  the  quality  of 
survival.
                  Radiation therapy is considered as the treatment of choice for palliation of 
painful bone metastases for many years 1,2.  Its main aim is relief of bone pain, prevention 
of  pathological  bone  fractures  as  well  as  its  healing,  with  anticipated  effect  upon 
improving mobility, function, and quality of life.
                   Also, data from retrospective studies 3,4  and prospective randomized trials 5, 6 
showed that  single fraction treatments may be as effective as multifraction regimens. 
Since single  fraction treatment  may be advantageous for  both patient  and institution, 
various single dose fraction schedules have been investigated 2, 3, 7–13. Yet, optimal single 
dose of RT required for pain relief is unknown, although one study showed that 8 Gy 
gives a higher probability of pain relief than 4 Gy 14.
                   Furthermore, a dose level in - between the 4 Gy and 8 Gy (namely, 6 Gy) also 
appeared to be effective in achieving pain relief 12, not very different from that achieved 
with 8 Gy. In order to define the “lowest” optimal single dose of RT in the treatment of 
patients  with  metastatic  bone  pain,  we  underwent  a  prospective  randomized  trial 
comparing two single-fraction regimens of RT exploring dose-response effect in this trial 
setting.
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                    The reason for evaluating a lower dose than one already proven to be 
effective (8Gy) is  two   fold ;  the possibility of reirradiation increases, in view of the late 
side effects, and  there was an assumption that the acute effects would be less with a 
smaller dose. 
EPIDEMIOLOGY
INCIDENCE
                     The exact incidence of bone metastases is difficult to determine.  Autopsy 
studies have reported bone metastases in up to 85% of the patients dying of breast, lung 
and prostate primaries.15,16  Most other primary tumors can metastasize to bone, including 
kidney,  thyroid,  endometrium,  cervix,  bladder,  and  gastrointestinal  tract  cancers,  but 
these sites account for less than 20% of patients with bone metastases.  14,16 Radiologic 
studies lead to antemortem diagnosis of bone metastases in about 50% of patients with 
metastatic cancer originating in breast, prostate, and lung cancer, but only in 3% to 15% 
of patients with gastrointestinal tumors  15,16. Some hematologic malignancies including 
myeloma and lymphoma can also cause significant pain and bone destruction.
SURVIVAL
                     The ultimate prognosis for patients with bone metastases is poor, with  
median survival typically measured in months rather than years. Overall survival depends 
on the primary site and the presence or absence of visceral metastases. 
                      Patients with bone metastases from lung cancer have short median survival  
durations of 6 months. However, patients with bone metastases from breast or prostate 
primary sites may have significantly longer survival times. In patients with bone-only 
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metastatic  prostate  or  breast  cancer,  median  survivals  of  2  to  4  years  have  been 
reported.17,18. 
                     Whether the survival time is only a few months or extends to multiple years, 
these  patients  will  often  require  active  treatment  because  of  pain,  difficulty  with 
ambulation  and  immobility,  hypercalcemia,  pathologic  fractures,  neurologic  deficits, 
anxiety, depression, spinal cord or nerve root compression, and general deterioration of 
quality of life 19.
SITES
                     The axial skeleton is the most common site of bone metastases, with  
metastases most frequently occurring in the spine, pelvis, and ribs. The lumbar spine is  
the single most frequent site  of  bone metastases  20.  In  the appendicular  skeleton,  the 
proximal femurs are the most common site of metastatic disease, and humeral lesions 
also occur frequently. The acral sites (feet and hands) are rarely involved. 
                    Certain skeletal sites are associated with specific areas of bone metastases. 
For  example,  scapular  metastases  are  seen  more  frequently  from  renal  primaries  21. 
Involvement of the skull is more common with breast primaries. The distal appendicular 
skeleton (tibia, fibula) and acral sites (especially the hands) are more common with lung 
primaries,  and  involvement  of  the  toes  is  seen  more  commonly  with  genitourinary 
primaries.
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PATHOPHYSIOLOGY
 NORMAL BONE            
                  There are primarily three types of cells within mature bone :  osteoblasts,  
osteocytes  and osteoclasts.   Osteoblasts originate  from osteogenic  cells,  found in the 
periosteum or endosteum. The osteogenic cells differentiate into osteoblasts when there is 
a mechanical or chemical stimulus for remodeling or repair. The osteoblasts build bone 
by  depositing  collagen  type  I  into  the  extracellular  space.  An  inorganic  complex  of 
calcium  and  phosphate  (hydroxyapatite)  is  laid  down  within  this  organic  matrix  to 
provide the strength and density of the bone. 
                   The osteoblasts then mature into osteocytes , which maintain the bone 
structure.    Osteoclasts are  multinucleated  giant  cells  that  originate  from pluripotent 
hematopoietic bone marrow cells and are adherent to the bone surface  22.  These cells 
create an acidophilic environment that causes dissolution of the hydroxyapatite crystals 
and proteolysis of the bone matrix.
                    The differentiation and activation of osteoclasts occurs because of the effects  
of a group of proteins that are related to tumor necrosis factor, including osteoprotegerin, 
receptor  activator  of  nuclear  factor-kB  (RANK),  and  the  RANK  ligand  (RANKL). 
Osteoblasts and stromal cells express RANKL and activated T cells may also release 
RANKL. The RANKL binds to the RANK receptor on osteoclast precursors, which then 
induces the formation of mature osteoclasts. 
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                  Osteoprotegerin is  a  decoy receptor  for  RANKL, and inhibits  the 
differentiation  and activation  of  osteoclasts  22.  The  destruction  of  bone  by  osteolytic 
metastases is mediated by the osteoclasts, not by the tumor cells. However, the factors 
that activate the osteoclasts are likely produced by the tumor cells including RANKL, 
interleukin-1, interleukin-6, and macrophage inflammatory protein . The mechanisms for 
osteoblastic  activation  are  not  clearly  delineated,  but  it  appears  that  bone  resorption 
occurs first even in osteoblastic metastases from prostate cancer 23.
                 Normal bone is constantly being remodeled in a cycle lasting about 120 days  
(3 to 6 months). For the first 20 days of the cycle, the bone is resorbed by osteoclasts. 
The bone is then rebuilt by osteoblasts during the next 100 days.
METASTASES TO THE BONE
           A metastases to the bone is a consequence of a cascade of events including  
(Mareel et  al., 1991 and Choong, 2003). 
1. progressive growth at the primary site, 
2. tumor neo-vascularization, 
3. detachment of tumor cells from the primary tumour, 
4. invasion in the neighbouring tissues 
5. intravasation into the blood stream, 
6. survival in the circulation,
7. homing and arrest at the level of the bone marrow, 
8. extravasation, 
9. evasion of the host defence,
10. growth and stimulation of the osteoclast mediated bone resorption .
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Fig. 1. The vicious circle of bone metastases.
                  
                          The vicious circle of a developing bone metastases is represented by the thick  
blue arrows. Cancer cells inside the bone marrow produce a cascade of enzymes which – through 
stimulation of stromal cells, osteoblasts, lymphocytes and osteoclast progenitorcells – eventually 
stimulates osteoclasts to destroy the bone. At the right side of the figure, the physiological pain  
pathway is represented. Pain receptors capture different pain signals, which are transported via 
sensory neurons (in green) and the spinal cord to the thalamus and finally to cortical neurons.  
Radiation induces apoptotic death, not only of tumour cells (thereby reducing pressure) but also 
of all other cells in the cascade. Inhibitory effects of radiation are shown in red lines. The name 
of tissue is in bold capital print. (Adapted from Mundy, 2002 and Mareel and Leroy, 2003).
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CANCER CELLS
                    The presence of large quantities of growth factors inside the actively  
proliferating  bone  marrow stimulates  growth  of  metastatic  tumour  cells  leading  to  a 
vicious  cascade  of  events.  Cancer  cells  -  like  inflammatory  cells  -  release  osteoclast 
activating factors, such as PTH and PTH releasing protein (PTHrP), Interleukin- 1(IL-1), 
IL-6, IL-11, Tumor Necrosis Factor (TNF), Transforming Growth Factor Beta (TGF-β), 
Epidermal  Growth  Factor  (EGF),  Platelet  Derived  Growth  Factor  (PDGF)  and 
prostaglandins. All these molecules can trigger osteoblasts and stromal cells to stimulate 
the differentiation and fusion of osteoclast progenitor cells.
OSTEOCLASTS
                    Activated osteoclasts eventually cause the breakdown of the bone matrix.  
Osteoclasts are specialized cells that originate from monocyte precursor cells under the 
influence of RANKL, the ligand of the Receptor Activator of NF-κB (RANK) on the 
osteoclast  precursor.  The naturally  occurring decoy receptor osteoprotegerin (OPG),  a 
member  of  the  TNF  receptor  family,  inhibits  the  effect  of  RANKL  on  osteoclast 
differentiation. RANKL is produced by osteoblasts and stromal cells as a regulator of 
bone formation and destruction. Free floating soluble RANKL is also able to stimulate 
the osteoclast  progenitors. OPG is now being proposed in clinical trials for the treatment 
of bone metastases through the capturing of the free floating RANKL molecules.
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                    Amongst other functions RANKL will also induce lymphocyte development  
and  can  thus  be  involved  in  the  inflammatory  reaction  in  the  immediate  vicinity  of 
metastatic  tumor cells.  Recently  it  was  shown  a  that  RANKL was produced by the 
osteoclasts thus suggesting an autocrine stimulating loop inside the osteoclast in both 
physiological and pathological conditions.
STROMAL CELLS
                    Other mechanisms that are involved in this tumour-host microevironment  
involve the  TGF-β and TNF produced by stromal  cells.  This  particular pathway was 
recently documented to be essential in the development of bone lesions in rheumatoid 
arthritis . TGF-β promotes the production of PTHrP produced by bone cells and tumour 
cells that, in its turn, stimulates bone turnover by enhancing the osteolytic action of the 
osteoclasts . TGF-β can, on the other side, also promote apoptosis of osteoclasts thereby 
reducing osteolysis. Recently it was shown that stromal cells - derived from normal bone 
marrow - produce monocyte chemotactic proteins (MCPs) that are involved in the bone 
marrow homing of multiple myeloma cell lines.
INFLAMMATORY CELLS
                  Prostaglandins - produced by the attracted inflammatory cells - are present in  
the bone metastases micro-environment and induce further inflammation. Inflammation is 
a  critical  element  in  tumour  progression.  The  tumour  microenvironment  is  largely 
orchestrated by inflammatory cells .
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                 Those inflammatory cells are responsible for the acute effects of inflammation, 
frequently resulting in pain. Synthesis and release of inflammatory cytokines mediate the 
effects. Cytokines can be defined as proteins produced by a cell in response to a variety 
of stimuli . They are secreted by producer cells and then influence the behaviour of target 
cells.  Many  classes  of  cytokines  are  known:  growth  factors,  lymphokines,  colony 
stimulating  factors,  transforming growth factors,  TNFs,  interferons.  It  is  important  to 
realize  that  cytokines  can  be  directly  produced  by  the  tumour  cells,  but  are  often 
produced in larger amounts by the inflammatory cells that are attracted by the tumour 
cells. 
                  The cytokines produced by the tumour cells usually aim at survival and 
proliferation of the tumour, while the cytokines produced by the inflammatory cells may 
help the organism to fight against the cancer cells, resulting in an inflammatory reaction 
which frequently causes pain. This inflammatory reaction is a very complex system, with 
many  synergistic  and  counteracting  cytokines  being  present  at  the  same  moment. 
Moreover,  many  cytokines  have  overlapping  biological  effects.  The  synthesis  and 
presence of cytokines will result in the production of other cytokines, with again different 
functions and effects, creating a complex network.
                  Blocking one pathway can force a cell to use another one as a kind of escape  
route, to eventually obtain the same effect, but via a previously unused and seemingly 
redundant  mechanism . TGF-β is produced by cancer cells and can act as a growth factor 
for  certain cells,  but  can also  block the  mitogenic  effects  of  EGF,  PDGF,  fibroblast 
growth factor (FGF) and insulin . Cancer cells losing the TGF- β receptor will lose at  
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least one survival limiting factor. But, while inhibiting growth, TGF-β at the same time 
stimulates  osteoclasts  and  thereby  helps  the  cancer  cells  to  invade  into  the  bone. 
Moreover,  e.g.  in  colon  cancer  cells,  TGF-  β  may  transform  fibroblasts  into 
myofibroblasts which will secrete other factors that promote invasiveness of the cancer 
cells .
                 Although cancer cells are self  and should not evoke an immune response, they 
are  often  surrounded  by  large  amounts  of  inflammatory  cells.  In  some  cases  these 
inflammatory cells may even make up more than 50 % of the tumour cellular volume. 
This also explains the clinical experience that anti-inflammatory drugs, like steroids or 
non-steroidal anti-inflammatory compounds can give a (temporary) decrease in tumour 
volume. Even routine antibiotics may reduce tumour volume, of course only in cases of 
infected tumours that are heavily loaded by inflammatory cells.
THE PREDILECTION OF CERTAIN TUMOR SITES TO METASTASIZE 
TO BONE
                   The apparent predilection of some tumors for certain sites in bone has been  
ascribed to the anatomic relationship between venous drainage of the primary site and the 
blood  supply  of  bones  that  are  common  sites  of  metastases.25,26,27,29   However,  most 
metastatic sites cannot be predicted from anatomic considerations alone. A number of 
animal tumors show preference for metastases to one or two specific organs, which might 
be explained by organ tropism.15
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 Possible mechanisms include the following 28 : 
1. Tumor cells disseminate equally to all organs, but preferentially grow in specific 
organs  (organ-specific  growth  may  be  stimulated  by  local  growth  factors  or 
hormones present in the bone or bone marrow); 
2.  Circulating  tumor  cells  may  adhere  preferentially  to  the  endothelial  luminal 
surface only    in specific bones, which may be mediated through organ-specific 
endothelial determinants such as glycoproteins. The endothelial cells of marrow 
sinusoids lack a basement membrane,  but have gaps between them that make the 
wall more penetrable by tumor cells than other  vascular elements 29 ; 
3.  Circulating tumor cells may respond to factors diffusing locally out of the bone, 
which  act  chemotactically  to  attract  the  cells.  Degradation  products  of  normal 
bone resorption are chemotactic for tumor cells in vitro .25 ,30
                     These chemotactic substances comprise connective tissue elements from 
bone such as type I  collagen and collagen fragments,  and their  presdence could also 
explain,  at  least  partially,  the  localization  of  tumor  cells  in  bone  in  vivo.  25 If  this 
mechanism contributes to localization of metastases to specific sites in bone, these sites 
must release more of the chemotactic substances than other sites.
                      The proteins Nm-23 and Awd may be important to the metastatic process in  
general, but current data are too preliminary to speculate about their possible role in bone 
metastases.31
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                      Metastases in bone are found almost invariably in the red marrow, and the 
bones most frequently involved are those with a high proportion of red marrow 32, more 
than 80% of bone metastases are found in the axial skeleton. The spine, pelvis, and ribs 
are often the earliest sites of metastases, whereas the skull, femora, humeri scapulae, and 
sternum are involved later. Different types of primary tumors do not show a significant 
difference  in  their  distribution  to  different  bones,  except  that  cancers  of  the  prostate 
bladder, cervix uteri, and rectum tend to involve the bones of the pelvis. 33 Solitary bone 
metastases are rare except for patients  with renal cell  carcinoma or neuroblastoma in 
which 5% to 10% of the patients may have a single site of bony involvement. 32,33 Bone 
metastases are usually wide spread by the time of their first clinical manifestion.
                       Bone metastases have local effects resulting in increased bone destruction  
(osteolysis), increased bone formation (osteosclerosis), or both.25, 34 Osteolytic metastases 
are the predominant types of lesions in most cancers, but a sclerotic appearance is seen in 
the majority of metastases from prostate cancer, in about 10% of metastases from breast 
cancer, and more rarely in those derived from other cancers.   Microscopically, there are 
no  qualitative  differences  between  lytic  and  sclerotic  metastases.  In  the  majority  of 
skeletal metastases, new bone formation develops simultaneously with bone destruction, 
and the radiologic appearance merely reflects the process that predominates.  25,32,34,35
                        A minority of patients may have diffuse involvement of the marrow  
without  radiographic  abnormalities.  Unbalanced  remodeling  of  bone  with  excessive 
resorption and minimal new bone formation appears to be the usual feature of multiple 
myeloma.36
17
PAIN DUE TO BONE METASTASES
                      The relationship between bone invasion and bone pain is unclear. Patients  
may have multiple bone lesions without related bone pain. Conversely, patients may have 
considerable  pain  without  radiologic  evidence  of  bone  metastases,  or  there  may  be 
dissociation  between the  perceived location of  the  pain and the  sites  of  known bone 
lesions.37
 Mechanisms that may cause pain from bone metastases include the following 38,39:
(1) stimulation of nerve endings in the endosteum resulting from release of chemical 
agents from the destroyed bone tissue such as prostaglandins, bradykinin, substance 
P, or histamine;
(2) stretching of periosteum by increasing size of the tumor; 
(3) fractures; and 
(4) tumor growth into surrounding nerves and tissues. 
                        Few of these mechanisms are supported by definitive data. Stimulation of 
nerve endings in the endosteum by chemical agents released from the destroyed bone 
tissue is probably the main mechanism of bone pain from small metastases; as metastases 
enlarge, stretching of the periosteum probably contributes to pain.
                      Pain from bone metastases is frequently the first symptom for which the 
patients will seek advice . Pain is a  complex experience that is based on the transduction 
of a noxious environmental stimulus in the periphery of the body and that is modulated 
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by  cognitive  and  emotional  processing  by  the  cortical  neurons  of  the  brain.  The 
subjective  nature  of  pain  has  hampered  the  development  of  randomised  trials 
considerably and has recently lead to initiatives to promote a universal language when 
reporting the palliative antalgic effects of any form of therapy for bone metastases .
                       In general there are two types of pain in patients with bone metastases. The 
first type is a continuous pain and is usually described as a dull aching pain that increases  
in  severity  over  time.  A  second  type  of  bone  cancer  pain  is  movement-evoked, 
breakthrough or episodic and is more acute in nature .
                       The pain from bone metastases can be explained by direct stimulation of  
afferent pain nerve fibres that are stimulated by mechanical injury or by a multitude of 
factors  present  in  the  complex  microenvironment  of  bone  metastases.  Local  tissue 
acidosis is a hallmark physiologic response to injury and inflammation and the degree of 
pain  is  correlated with the  magnitude of  acidification.  A number of  acid-sensing ion 
channels (ASIC3/VR1) are found on sensory neurons (Julius and Basbaum, 2001). 
Stimulus                                              Representative receptor/moleculartargets
Nerve Growth Factor (NGF)                 Transmembrane receptor Kinase A (TrkA)
Bradykinin  receptor                   Bradykinin       (G-protein coupled) membrane 
Serotonin                                               5-Hydroxy Tryptamine receptor (5-HT3)
Adenosine tri phosphate (ATP)            ATP gated ion channel (P2X3)
H+                                                         Acid-sensing ion channel (ASIC3)
                                                              Vanilloid receptor (VR1)
Lipids                                                    Prostaglandin E2 (PGE2), VR1
Pressure                                                 Degenerin family of ion channels (DEG/ENaC)
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CLINICAL PRESENTATION
                    The morbidity associated with metastatic bone disease, often referred to as 
skeletal-related  events  or  SREs, includes  pain  that  may require  opiates,  the  need for 
radiotherapy  and/or  surgery,  hypercalcemia,  pathologic  fractures,  and  spinal  cord 
compression.
PAIN
                      The most common symptom is pain. Pain may initially be either a well-
localized focus of pain or a diffuse ache, typically worse at night and often not relieved 
by lying flat. Pain from extremity lesions tends to be well defined, in contrast to spine 
and pelvic sites, which produce vague, diffuse symptoms. Eventually the pain worsens 
with weight-bearing activity. Initially, pain results from the physical presence of tumor in 
the bone, with the release of inflammatory mediators, neuropeptides, and cytokines, as 
well  as  elevation  of  the  intraosseous  pressure  due  to  tumor  mass  effect,  and  causes 
irritation of intraosseous and per-iosteal nerve endings.
                      Functional pain is caused by the mechanical weakness of the bone that can  
no  longer  support  the  normal  stresses  of  daily  activities.  Mechanical  pain  is  more 
typically  associated  with  the  focal  bone  loss  within  lytic  lesions;  however, 
radiographically blastic lesions may also weaken the bone through associated areas of 
osteolysis  that  are  sufficient  to  compromise  structural  integrity.  The  development  of 
functional pain may be a marker for bone at risk for fracture.
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HYPERCALCEMIA
                     Hypercalcemia of malignancy is the most common metabolic complication 
of malignancy. In breast carcinoma, hypercalcaemia traditionally occurred in around 10% 
to  20% of  patients.40 However;  the  incidence  has  fallen  markedly  over  the  past  two 
decades through the increasingly widespread use of bisphosphonates to prevent skeletal 
complications. 
                    Hypercalcemia is mediated by up to three mechanisms in metastatic bone 
disease. Excessive osteolysis may release more calcium than the kidney can cope with. 
Advanced metastatic disease with severe bone destruction at multiple sites is the more 
frequent cause of this complication. In addition, tumors, particularly of squamous cell 
histology,  may  secrete  parathyroid  hormone-related  protein  (PTHrP) that  will  both 
mobilize skeletal calcium and stimulate the kidney to reabsorb calcium inappropriately. 
With  a  decrease  in  activity  because  of  pain,  disuse  osteolysis  will  exacerbate  the 
hypercalcemia. 
                    With mild degrees of hypercalcemia, patients are often asymptomatic but, as 
the level of calcium rises, patients become progressively dehydrated and may develop 
fatigue,  lethargy,  nausea,  vomiting,  anorexia,  and  disorientation.  Rehydration  and 
initiation of bisphosphonate therapy will restore calcium levels to normal and repeated 
treatments may prevent recurrent episodes.
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PATHOLOGIC FRACTURES
                        
                  Pathologic fractures may be the first sign of metastatic bone disease. In breast 
carcinoma, as many as 35% of patients with bone disease experience a fracture.   Breast, 
lung,  renal,  and thyroid cancer  have been the  most common cancers  with pathologic 
fracture, but even in endocrine resistant prostate cancer, where osteoblastic metastases 
are typical, annual fracture rates in excess of 20% may be seen.
EVALUATION
PHYSICAL EXAMINATION
                      
               The physical examination is an important step in evaluating a patient with bone  
metastases.  It  may  help  make  decisions  regarding  appropriate  subsequent  imaging 
studies. Firm palpation will often elicit the specific area of pain, with ‘point tenderness’ 
often  pointing  directly  to  the  affected  area  in  the  bone.  It  is  important  to  carefully 
evaluate the entire skeletal system with examination, as intense pain at one site often 
masks subjective reports of pain at other sites. A careful physical examination may reveal 
hidden pain in other locations.  A thorough neurologic examination is also important, 
especially in patients with spinal metastases, to carefully evaluate for the possibility of 
spinal cord, cauda equina, or nerve root compression.
PLAIN RADIOGRAPHS
22
                     For symptomatic patients with point tenderness, plain radiographs are 
typically the most appropriate first imaging study. Such radiographs are easy to obtain 
and inexpensive. The appearance of bone metastases on x-rays varies depending on the 
primary site and histology. Most bone metastases from lung cancer and breast cancer 
appear  osteolytic,  whereas  most  from prostate  cancer  appear  osteoblastic  .  However, 
nearly all bone metastases have components of both osteolytic and osteoblastic processes. 
The  primary  disadvantage  of  plain  radiographs  is  that  small  lesions  are  rarely  seen. 
Approximately 30% to 50% of the bone mineral content must be lost before the lesion 
will be apparent on x-rays.
NUCLEAR MEDICINE BONE SCAN
                         Technetium-99 m bone scintigraphy  is the best method for screening  
patients at risk for bone metastases and is  useful to evaluate the extent of metastatic  
disease in the bone. Bone scintigraphy is an indicator of osteoblastic activity. Because 
multiple  myeloma  is  frequently  purely  osteolytic,  bone  scans  are  less  useful  for 
evaluating extent of disease in myeloma. 
                       Bone scintigraphy is not specific for metastatic disease, and positive  
findings must often be confirmed using other imaging studies. A confirmatory study is 
especially important in a weight-bearing bone such as the proximal femur. False-positive 
readings may be seen in areas of arthritis,  trauma, or Paget's disease. In addition, the 
osteoblastic  activity  in  healing  bone  after  treatment  may  give  the  appearance  of 
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progressive  disease.  False-negative  readings  may  occur  in  fast-growing,  highly 
aggressive tumors, especially if these are mainly osteolytic.
CT SCANS
                      Computed tomography  scans are more sensitive than plain radiographs, 
and may be better able to localize the lesion within the bone. However, CT scans are 
more expensive, more time-consuming, and may not be useful as a screening tool for 
skeletal metastases. The CT may be useful in defining the extent of cortical destruction 
and helping to assess the risk of a pathologic fracture . In addition, the CT scan may be 
used  to  guide  needle  biopsies  to  obtain  a  tissue  diagnosis.  CT  scans  have  limited 
usefulness in detecting marrow involvement, but are much better than plain radiographs 
at evaluating soft tissue extension of disease.
MRI SANS
                      Magnetic resonance imaging  is better than plain radiography or nuclear  
medicine  bone  scintigraphy  at  assessing  the  involvement  of  trabecular  bone  (red 
marrow), especially in the vertebral bodies. The findings are typically best seen on T1 
contrast-enhanced images and short  tau inversion recovery (STIR) images.  Metastatic 
prostate cancer is visible as high-intensity lesions on the STIR images, and is visible prior 
to its appearance on bone scintigraphy . In addition, MRI scans are useful in determining 
the involvement of neurovascular structures. MRI scans are not useful as a screening tool 
for bone metastases. However, MRI scans may be more sensitive than bone scintigraphy 
in the vertebral body region . The sensitivity of MRI scanning has been reported as 91% 
to 100%, compared with 62% to 85% for bone scintigraphy . In addition, MRI images 
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can help distinguish whether a vertebral body compression fracture is from malignancy or 
from osteoporosis.
PET SCAN
                  Positron emission tomography  scanning evaluates areas of increased  
metabolic  activity,  most  commonly  using  the  18-fluorodeoxyglucose  (FDG)  isotope. 
These scans are useful in detecting osteolytic bone metastases, but are less sensitive for 
osteoblastic metastases. In addition, precise determination of the location of lesions is 
difficult with PET scans, but the use of simultaneous CT scans allows for much better 
localization of the abnormal FDG uptake . PET scans may be useful as a whole-body 
screening tool . Comparative studies have shown PET scans to be more sensitive than Tc-
99 m scintigraphy or whole-body MRI scans in detecting bone metastases . There may be 
limitations in the sensitivity of PET scanning in certain areas such as the skull, where the 
intense physiologic uptake from the adjacent brain parenchyma may obscure small skull 
metastases.
THERAPEUTIC MODALITIES
                   Optimal management requires a multidisciplinary team. Medical treatment,  
radiation  therapy,  surgery,  and bone  targeted  treatment  with  the  bisphosphonates  are 
combined depending on the biology of the disease, extent of the skeletal involvement, 
and the life expectancy of the patient.
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PAIN MANAGEMENT 
                  The majority of patients with bone metastases will experience pain during 
their disease course, and pain control can significantly improve their quality of life. Pain 
management may be achieved either by debulking disease using cytotoxic therapy or by 
symptomatic control with pharmacologic interventions. The use of a validated pain scale, 
gives the patient an opportunity to describe the severity of pain and the interference of 
pain  with  function  in  a  manner  that  can  be  understood  both  by  the  patient  and  the 
physician . This also allows for comparisons of pain levels over time, to better assess the 
effectiveness of treatments.
WHO ANALGESIC LADDER
                   Pain control can be achieved in the majority of patients using the World  
Health Organization analgesic ladder.
• Step I     uses nonopioid analgesics such as acetaminophen or non steroidal 
anti-inflammatory  drugs; 
• step II    uses weak opioids such as codeine; 
• step III   uses strong opioids such as morphine. 
                   These medications are increased as necessary until the patient is free of pain.  
Typically, the medications are given on a routine schedule (‘by the clock’) rather than 
waiting until a certain level of pain (‘on demand’).Using this schedule, 70% to 76% of 
patients  will  have  good  pain  relief  .  Adjuvant  medications  such  as  gabapentin  or 
amitriptyline  may  be  added  for  neuropathic  pain.   Antianxiety  or  antidepressant 
medications may also be of benefit in selected patients.
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RADIATION THERAPY
EFFECTS OF IRRADIATION ON BONE METASTASES
                   The main goal of palliative radiation treatment is the relief of pain or 
dysfunction caused by the bone metastases. For most patients who achieve pain relief 
after  irradiation  this  lasts  for  two-thirds  of  their  remaining  life  (Perez  et  al.,  2004). 
Adequate  management  of  this  group  of  patients  is  important  for  a  number  of 
reasons:
• Bone pain secondary to metastases is the most common pain syndrome requiring 
palliative treatment in cancer patients; 
• Patients with predominant bone metastases have longer duration of survival than 
patients with predominantly visceral metastases; 
• Complications of bone metastases are common and produce high morbidity.
                    It is a common misconception that ionizing radiation will result in a decrease  
in normal ossification. External beam irradiation produces ossification in 65% to 85% of 
lytic metastases in unfractured bone. Some of the ossification may occur by heterotopic 
ossification  within  the  lesion,  however,  in  most  cases,  there  is  formation  of  mature 
organized bone in the healed lesion, seemingly by direct osteogenesis .
                   Radiation therapy has been reported to be effective in palliating painful bone  
metastases, with partial pain relief seen in 80% to 90% of patients, and complete pain 
relief  in  50%  of  patients  .  These  data  are  primarily  from  studies  using  physician 
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evaluation of pain. When patient evaluation of pain is used, pain improvement is seen in 
60% to 80% of patients and complete pain relief is seen in 15% to 40% of patients . 
                  The response to treatment depends on a large number of factors, including 
sex,  primary  site  and  histology,  performance  status,  type  of  lesion  (osteolytic  vs. 
osteoblastic),   location of the metastases,  weight-bearing vs. non-weight-bearing site,  
extent of disease, number of painful sites,  marital status,  level of pain prior to treatment. 
The effectiveness of the treatment also depends on the goal: 
• palliation of pain, 
• prevention of pathologic fracture, 
• avoidance of future treatments, 
• local control of the disease.
 The doses required and volumes treated may be quite different for each of these goals.
                 When radiation travels through a living cell, it can damage the reproductive 
material in the cell directly and indirectly. Direct damage includes base deletions and 
single and double strand breaks in the DNA chain. Indirect damage occurs when radiation 
interacts with water molecules in the cell,  releasing toxic free radicals.  Repair of the 
damage is possible both in normal cells and cancer cells. Cancer cells have less capacity 
to repair damaged DNA, and hence a therapeutic ratio can be exploited.
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                 Radiation can be delivered by an external beam of radiation directed at the site 
of interest, or in the form of radionuclide given intravenously as an inorganic soluble 
compound. 
MECHANISM
                    Although treatment by external irradiation is successful in most patients the  
exact mechanism of action is unknown (Hoskin, 2003).
                    The doses used - though less than a radical course of radiotherapy - will  
cause high levels of tumour cell kill. There will therefore be a substantial reduction in the 
number of viable tumour cells within the radiation field and in due course this will result 
in shrinkage of  the tumour bulk.  Once the tumour cells  are removed from the bone,  
osteoblastic repair will partially restore the integrity of the bone. Certain features of the 
response - like pain diminishing after a few sessions - suggest that tumour shrinkage itself 
is unlikely to account for the early period of pain relief seen.
                     The absence of a dose response relationship suggests that tumour shrinkage  
may not be that important since tumour shrinkage would not be expected with some of 
the very low single doses - down to 4 Gy - which have been shown to cause pain relief. 
Furthermore there appears to be no obvious relationship between the radiosensitivity of 
the primary tumour and the response on pain. The striking clinical observation that some 
patients  experience  symptom  relief  within  24  hrs  after  the  irradiation  leads  to  the 
hypothesis that early reacting and very sensitive cells and the molecules they produce are 
involved in this answer. 
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                    Obvious candidate cells are the inflammatory cells that are largely present in  
the  bone  metastases  micro-environment.  Reduction  by  ionizing  radiation  of  the 
inflammatory  cells  inhibits  the  release  of  chemical  pain  mediators  and  is  probably 
responsible for the rapid reaction seen in some patients (Mercadante, 1997).  
                   Other candidate cells are the osteoclasts. Osteoclastic activity is an early and 
important  response  to  tumour  cell  invasion.  Recently  it  has  been  demonstrated  that 
urinary markers of bone resorption (and thus osteoclastic activity) and pain relief after 
radiation treatment were correlated (Hoskin et al., 2000).
                  Doses of 5 Gy given to metatarsal bones of embryonic mice resulted in a 
selective elimination of the precursor cells for osteoclast formation (Scheven et al., 1986). 
A  clear  dose-response  relationship  between  the  dose  of  ionizing  radiation  and  the 
decrease in osteoclast number in vitro was observed (Tsay et al., 1995). The calculated 
life span of the osteoclast in this study was 9 to 10 days. In a further investigation by the 
same group  (Tsay et al.,  1999) they showed that  in the first  weeks after exposure to 
moderate doses of ionizing radiation the number of osteoclasts did not diminish.
                   Other studies have shown that the influx of osteoclast precursor cells in vivo  
is effectively suppressed by ionizing radiation (Comas, 1970). The resorbing activity of 
the osteoclast is less radiosensitive but can be inhibited, in a dose dependent way, by a  
dose of at least 5 Gy, as was established by morphometric and biochemical methods in a  
mouse embryo model (Scheven et al., 1985). 
                   Another indirect hint to the importance of the effect of ionizing radiation on 
the inflammatory cell / osteoclasts comes from work done with cyclooxygenase-2 (COX-
30
2) selective inhibitors. In a mouse model it was shown that the chronic administration of 
a COX-2 inhibitor attenuated the pain, reduced the tumour burden, osteoclastogenesis 
and bone destruction by more than 50%  (Sabino et al., 2002). In the control mice the 
increased  bone  resorption  was  explained  largely  by  the  sarcoma-induced  osteoclast 
proliferation and hypertrophy.
                   The COX-2 inhibitor  reduced this  proliferation and hypertrophy.  
Prostaglandins (particularly PGE2) modulate the osteoclast function and by reducing the 
production of PGs there is a reduction in proliferation and hypertrophy of the osteoclasts. 
Besides the analgesic effect of ionizing radiation and bisphosphonates a secondary goal is 
the re-ossification of the osteolytic lesion. 
THE DOSE, TARGET VOLUME AND FRACTIONATION
                   The target volume for primary irradiation of  a bone metastases is defined by 
the anatomical borders of the bone marrow compartments inside the bone. The margins 
are adjusted for motion uncertainty depending on the site of the bone metastases.
                   All of the studies were randomized but blinding was often impossible.  
Radiotherapy, in these trials produced complete pain relief at one month in 25% of the 
patients.  A  relief  of  at  least  50%  at  one  month  was  achieved  in  41%  of  patients. 
Analyzing  the  various  fractionation  schedules  there  were  no  significant  overall 
differences found. All trials taken together showed that half of the patients who achieved 
complete relief took four weeks to achieve it. 
                  With 43 different fractionation schedules, it was impossible to obtain the 
strength of evidence needed to show if there is a difference in efficiency between a single 
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fraction  and  multiple  fractions  radiation  treatment  for  pain  relief.  Hypo  fractionated 
schedules result in somewhat more acute toxicity. The whole of the available evidence 
suggests however that an increase in the number of fractions does not translate in an 
increase of the therapeutic benefit.    
RESULTS OF PUBLISHED CONTROLLED CLINICAL TRIALS ON DOSE AND
FRACTIONATION  FOR  THE  PALLIATION  OF  PAINFUL  BONE 
METASTASES
(UPDATE JAN 2004)
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Reference Comparison Number of 
patients 
Randomized
Primary endpoint 
p-value
Tong 1982 A: 20 Gy in 5 fractions vs
B: 40.5 Gy in 15 fractions
266 n.s.
Madsen 1983 A: 20 Gy in 2 fractions vs
B: 24 Gy in 6 fractions
57 n.s.
Price 1986 A: 8 Gy in 1 fraction vs
B: 30 Gy in 10 fractions
288 n.s.
Okawa 1988 A: 20 Gy in 10 fractions vs
B: 22.5 Gy in 5 fractions vs
C: 30 Gy in 15 fractions
80 n.s.
Hirokawa 
1988
A: 25 Gy in 5 fractions vs
B: 30 Gy in 10 fractions
128 n.s.
Cole 1989 A: 8 Gy in 1 fraction vs
B: 24 Gy in 6 fractions
29 n.s.
Reference Comparison Number of 
patients 
Randomized
Primary endpoint 
p-value
Kagei 1990 A: Single fraction vs
B: multiple fractions
27 n.s.
Hoskin 1992 A: 4 Gy in 1 fraction vs
B: 8 Gy in 1 fraction
270 n.s.
Porter 1993 A: < 10 Gy in 1 fraction vs
B: 20 Gy in 5 fractions vs
C: 30 Gy in 10 fractions
125 n.s.
Rasmusson 
1995
A: 15 Gy in 3 fractions vs
B: 30 Gy in 10 fractions
217 n.s.
Niewald 1996 A: 20 Gy in 5 fractions vs
B: 30 Gy in 15 fractions
97 n.s.
Gaze 1997 A: 10 Gy in 1 fraction vs
B: 22.5 Gy in 5 fractions
265 n.s.
                The RTOG trial 97-14 is an example of a large and recently reported trial that 
had as objectives:
1.  to determine whether 8 Gy in a single fraction provides equivalent pain relief 
compared to   30 Gy in 10 fractions for patients with painful bone metastases, 
2.  to determine the duration of pain relief,
3.  to determine the effect on quality of life measures;
4. to determine the incidence of pathologic fracture and
5. to determine cost-effectiveness of therapies in terms of cost/quality adjusted life 
years. 
                         
                     Preliminary results (Hartsell et al., 2003) were presented in abstract form at 
the  ASTRO meeting  2003  and  confirm  the  data  from the  other  trials:  there  was  no 
difference in pain relief when comparing both treatment regimens.
                       
                    We can conclude that single fraction radiation treatment compared to  
multiple-fraction  radiation  treatment  provides  equal  palliation  and quality  of  life  and 
based on a Dutch study (Van den Hout et al., 2003) single fraction treatment has a lower 
medical and societal cost. Therefore single fraction radiation treatment is the treatment of 
choice for cancer patients with painful, uncomplicated bone metastases.
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                 In an effort to investigate the place and role of single fraction RT in the 
treatment  of  painful  bone  metastases,  researchers  from the  Royal  Marsden Hospital, 
Sutton, UK conducted three consecutive studies. 
                        
                 In their first study 6, single dose of 8 Gy  was found to be as effective as 
multifraction regimen consisting of ten daily fractions of 3 Gy, considered by many as 
“standard” regimen for treating bone metastases: no difference was found in CR rate, 
speed of onset or duration of pain relief between the two regimens. Thus, for the first 
time, it was shown that single fraction RT can be considered effective and safe option in 
palliation of bone metastases. Since no effect of histology was found in that study 6  and 
single doses lower than 8 Gy could have also been effective as the one investigated. Two 
additional studies investigated the efficacy of a single fraction RT in palliation of bone 
metastases in last decade. 
 REIRRADIATION
                        
                 As effective systemic treatment and better supportive care result in improved 
survival, certain subsets of patients with bone metastases have longer life expectancies 
than before.  An increasing number of patients  outlive  the  duration of  the  benefits  of 
initial palliative radiotherapy for symptomatic bone metastases, requiring reirradiation of 
the previously treated sites. Additionally, some patients fail to respond initially but may 
benefit from reirradiation. Among the radiation trials comparing single versus multiple 
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fractionation  schemes,  reirradiation  rates  varied  from 11% to  42% following  single-
fraction and 0% to 24% following multiple-fraction schedules. 
                       
                  There are at least three scenarios of ‘failure’ where reirradiation may be  
considered. Response to reirradiation  may be different for each of these scenarios:
• No pain relief or pain progression after initial radiotherapy,
• Partial  response with initial  radiotherapy and the  hope to  achieve further  pain 
reduction with more radiotherapy, and
• Partial or complete response with initial radiotherapy but subsequent recurrence of 
pain.
                  In summary, available data support the reirradiation of sites of metastatic bone 
pain  following  initial  irradiation,  particularly  where  this  follows  an  initial  period  of 
response.  There  is  also  limited  evidence  that  a  proportion  of  nonresponders  would 
respond to reirradiation.  However, there remains a small group of patients who appear to 
be nonresponsive to any amount of palliative radiotherapy. Although the data do support 
the  clinical  practice  of  reirradiation,  the  preferred  dose  fractionation  at  time  of 
reirradiation  is  unknown.  A phase  III  international  randomized  trial  of  single  versus 
multiple fractions for reirradiation of painful bone metastases is ongoing and will help 
address  the  practical  questions  facing  radiation  oncologists  when providing palliative 
radiation services.
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HEMIBODY RADIATION THERAPY
                 Hemibody irradiation (HBI), or wide-field radiation therapy, refers to the  
technique of treating a large portion of the body with external-beam irradiation. Although 
the term hemibody irradiation is used, typically the field does not cover half of the body, 
but more accurately treats about one third of the body. The treatment has been used for  
palliation  of  symptoms and as  an adjuvant  to  prevent  the  development  of  new bone 
metastases.  The  treatment  for  palliation  of  pain  is  most  useful  in  patients  who have 
diffuse, widespread bone metastases.
                   The treatment volumes have been divided into upper, middle, and lower HBI.  
The fields for upper HBI cover the thorax and abdomen from the neck to the top of the 
iliac  crests.  For  midbody  HBI,  the  fields  include  the  abdomen  and  pelvis  from  the 
diaphragm to the ischial tuberosities, and for lower HBI treatment, the field borders are 
from the top of the pelvis to the inferior portion of the femurs. 
                  RTOG 78-10 was a dose-searching prospective protocol evaluating the 
maximum tolerated dose (MTD) for single-dose HBI 40. The MTD for middle and lower 
hemibody treatment was 8 Gy. The MTD for the upper HBI was 6 Gy if the lung dose 
was uncorrected and 7 Gy if lung corrections were used.
  
37
LITERATURE REVIEW
Most of the studies using high-dose single fraction RT in the treatment of painful bone 
metastases in the last three decades with a total of more than 1500 patients are given .
STUDIES USING SINGLE -FRACTION RT
AUTHOR(REF) YEAR RT DOSE(Gy) OVER ALL 
RESPONSE 
RATE(%)
Vargha et al. 1969 18 90
Penn et al. 1976 15 89
Hendricksen et al. 1976 9 88
Jensen  andRoesdahl 
et al.
1976 7.5 85
Price et al. 1986 8 73
Barak et al. 1987 6
8
10
71
Price et al. 1988 4 43
Karstens et al. 1989 4 45
Hoskin et al. 1992 4
8
44
69
Uppelschoten et al. 1995 6 88
Jeremic et al. 1998 4 59
6 73
8 78
Metin Guden et al. 2002 6 88.7
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                   If we exclude the two initial studies that used extremely high single doses of  
18 Gy and 15 Gy, respectively (and produced overall response rates not very different 
from those obtainable with 6–10 Gy), all other used single fractions in the range 4–10 
Gy.  Although different means of evaluation of patients response to treatment have been 
used, overall response rates seem to follow the pattern as we have observed it during 
current study. 
STUDIES  USING  SINGLE  FRACTION  6Gy  RT  IN  PAINFUL  BONE 
METASTASES
                Barak et al 12  in 1987 reported on a study that evaluated the efficacy of high 
single doses (6,8, and 10 Gy, respectively) of radiation on pain relief. Among the 94 
evaluable patients, 12 (13%) patients received 6 Gy, 66 (70%) received 8 Gy, and 16 
(17%) patients received 10 Gy.  Response to radiation was 71% which lasted up to 6  
months in 37% patients and up to 12 months in 21% patients in  6Gy arm. Most patients 
who achieved pain relief did so in the first week post-RT. There were no differences in 
pain relief among the patients with different metastatic sites treated or with different 
histologies.
                 Uppelschoten et al 41 in 1995 reported on the use of a single fraction RT of 6 
Gy in palliation of bone metastases in 170 patients. Pain relief was achieved in 88% 
patients with CR observed in 39% patients. The pain relief was observed in the first  
week post-RT in 58% patients.
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                Jeremic et al  42 in 1998 reported on a study that evaluated the efficacy of high 
single doses (4,6, and 8 Gy, respectively) of radiation on pain relief. Among the 327 
evaluable patients, 109  patients received 4 Gy, 108 received 8 Gy, and 110 patients 
received 8 Gy.  Response to radiation was 59 % in 4Gy arm, 73% in 6Gy arm and 78% 
in 8Gy arm. The pain was observed in the first week post-RT in 19.6% patients.
                 Metin Guden et al 43    in 2002 reported on the use of a single fraction RT of 6 
Gy in palliation of bone metastases in 62 patients. Pain relief was achieved in 88.7% 
patients with CR observed in 37.1% patients. The pain relief was observed in the first 
week post-RT in 53% patients.
                
                 Of additional importance is the fact that series using single fraction of 6 Gy 
produced overall response rates of approximately 70–75% [as high as 88% in a series of 
Uppelschoten et al  and 88.7% in  Metin Guden et al   ].  Since single fraction RT of 6 Gy 
did not produce results inferior to that obtained with 8 Gy, further studies are needed to 
get more informations regarding optimal single fraction RT in the treatment of painful 
bone metastases.
                
                 There are no sufficient data to support a clear statement concerning dose-
response relationship and response duration beyond 3 months for single fraction RT in 
the treatment of painful bone metastases.
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                               AIM OF THE STUDY
              The present study aims at comparing   pain relief obtained with (trial arm) 6Gy 
single  fraction radiotherapy against  8Gy single  fraction radiotherapy (control  arm) in 
painful bone metastases.
               The study also aims at comparing the Toxicity , Infield Events  involved with 
the above two therapeutic protocols.
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MATERIALS AND METHODS
STUDY PERIOD :  From July 2008 up to June 2009
ELIGIBITY CRITERIA:  sixty patients with painful bone metastases who satisfied 
the following eligibility criteria were included in this study.
1. Age > 18 years. 
2. Genders:  Both Male and Females
3. Performance status: ECOG  0 – 3.
4. Histological or cytological diagnosis of malignancy associated with radiological 
evidence of painful bone metastases from any primary tumor site.
5. If patients with two sites of pain requiring separate treatment are to be entered, the 
same randomized treatment option will be used for both sites, but response at each 
site will be scored and analyzed separately. 
6. Anticipated remaining life of at least 12 weeks (3 months) .
7. Pain due to bone metastases.
8. Evaluable pain history.
9. Informed consent
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EXCLUSION CRITERIA   :
1. Primary histology myeloma .
2. Sites of previous RT or previous radioisotope treatment. 
3. Bisphosphonate treatment.
4. Previous surgical intervention at the same locus.
5. Complicated  bone  metastases  (pathological  fractures,  metastatic  spinal  cord 
compression) conditions or circumstances, which may interfere with treatment or 
follow-up. 
                               
 ARMS OF THE TRIALS:
ARM 1:  TRIAL ARM : 6 Gy single fraction; mandate first treatment ,if 
moderate or severe pain persists or recurs (as measured by categorical pain scale 
or VAS greater than 50 mm),  >4 weeks after initial RT, retreat with 6 Gy 
single fraction; second retreatment is optional if moderate or severe pain recurs 
(as measured by categorical pain scale or VAS greater than 50 mm), 
 
ARM 2 :CONTROL ARM : 8 Gy  single fraction; mandate first treatment 
if moderate or severe pain persists or recurs (as measured by categorical pain 
scale or VAS greater than 50 mm),  >4 weeks after initial RT, retreat with 8 Gy 
single fraction; second retreatment is optional if moderate or severe pain recurs 
(as measured by categorical pain scale or VAS greater than 50 mm), 
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PRETREATMENT WORK - UP
1. Complete clinical examination.
2. Complete blood counts including Hemoglobin assay.
3. Biochemical investigations to assess renal function.
4. Histopathological documentation.
5. Chest X-ray.
6. Skeletal survey /  Bone scan.
RADIOTHERAPY DETAILS:
 The radiation is given by  Telecobalt machine (Theratron Phoenix ). 
                Direct fields are used to treat vertebral column and parallel opposed fields are  
used to treat pelvis, hip, and long bones. Doses are specified at 5 cm depth for spine 
fields and to the midplane when parallel  opposed fields are used.  Rib metastases are 
treated with one direct field, dose specification on the dose maximum.
                When  treating lower thoracic or lumbar-sacral or pelvic/hip field, inevitably a 
varying volume of gastrointestinal tract was included in the treatment volume. Measures 
were taken to prevent acute side effects such as nausea and vomiting or radiation-induced 
enteritis  by  placing adequate  blocking and administering  appropriate  medication (e.g. 
antiemetics).
Tumor doses of  6Gy, 8Gy are given in a single fraction to patients in the two treatment 
groups.                       
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RADIOBIOLOGICAL COMPARISON 
RELATIVE EFFECTIVENESS (RE)
It denotes the relative effectiveness per unit dose for fractionated beam therapy
RE = 1+ d/ (α/β)      d- Dose per fraction, α damage (irrepairable), β damage (repairable).
High α/β  - characteristic of cell with little repair capability
e.g. tumour cells [from 5 - 20 Gy]
Low α/β - characteristic of  cell with high repair potential
e.g.late responding normal tissue [1-4 Gy]
CALCULATION OF RELATIVE EFFECTIVENESS:
 Early reacting tissue  (α/β = 10 Gy,)
 Late reacting tissue (α/β = 3 Gy )
RELATIVE EFFECTIVENESS (RE) FOR 8 GY
• Early reacting tissue  ( REe )  =  1+ 8/ 10  =  1.8
• Late reacting tissue   (RE l)    =  1+ 8/3     =  3.6
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RELATIVE EFFECTIVENESS (REF) FOR 6 GY
• Early reacting tissue  ( REe )  =  1+ 6/ 10  = 1.6
• Late reacting tissue   (RE l)    =  1+ 6/3     =  3.0
BIOLOGICAL EFFECTIVE  DOSE :
BED  is  the  product of the total dose and the  relative effectiveness.
BED = Nd [ 1+d/(α/β)]       N – Number of fraction ,  d-  Dose per fraction 
CALCULATION OF BED
BIOLOGICAL EFFECTIVE  DOSE FOR 8 GY
• BED for Early reacting tissue  =  8 x 1.8  =  14.4Gy  
• BED for late reacting tissue     =  8 x 3.6  =  28.8 Gy
BIOLOGICAL EFFECTIVE  DOSE FOR 6 GY
• BED for Early reacting tissue =  6 x 1.6  =    9.6Gy  
• BED for late reacting tissue    =  6 x 3     =   18 Gy
BED 8Gy - SINGLE # 6Gy - SINGLE #
Early reacting tissue  14.4 Gy 9.6 Gy
Late reacting tissue    28.8 Gy 18 Gy
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TREATMENT VERIFICATION : X – ray simulation.
D2,D3,D4 VERTIBRAL METASTSES
L5 VERTIBRAL METASTSES
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PAIN ASSESSMENT
          On the day of treatment planning or performing the irradiation, responsible 
radiation oncologist met the patient accompanied by at least one family member/relative 
judged to be the person that would spend most of the time with the patient and the pain 
chart was explained. The initial pretreatment assessment was made by the patient at this 
stage. Followed  by pain assessment performed weekly i.e. 1,2,4, weeks after completion 
of radiation and again on eighth week after radiation.
PAIN SCALE
Visual analogue scales (VAS)
          The VAS is an unmarked line with extremes marked as no pain and worst pain. 
Patients are asked to mark the point in the line that describes their pain.
Categorical numerical rating scales (NRS) --  11 point scale
         The NRS is similar to the VAS but uses numbers or gradations that indicate the 
severity of the pain experience.
48
Categorical verbal rating scales (VRS) --  4 point scale
         A VRS involves a sequence of words describing different intensity levels of pain 
such as:   0- None,  1-3 Mild, 4-7 Moderate, 8-10 Severe.
FOLLOW UP PERIOD : minimum 6 month.
            The primary endpoint is clinically significant pain relief in the first six months of 
follow-up  evaluated  with  the    IAEA  (International  Atomic  Energy  Agency)  pain 
measurement score measuring pain severity and pain frequency.
The pain score is obtained by multiplying pain severity by pain frequency. 
Pain severity is classified as 0 (none), 1 (mild), 2 (moderate) and 3 (severe). 
Pain frequency is classified as 0 (none), 1 (occasional = less than daily), 2(intermittent= 
at least once daily) and 3 (constant). 
               Analgesic use is recorded before and after treatment.
The narcotic score is obtained by multiplying drug severity by drug frequency.
 Drug severity is  classified as 0 (none given),  1  (analgesic),  2 (mild narcotic)and 3 
(strong narcotic).
 Drug frequency is classified as 0 (none given), 1 (less than once daily), 2 (once daily) 
and 3 (twice or more daily).
RESPONSE ASSESSMENT:
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 Complete response (CR) is defined as a pain score of 0.
 Partial response (PR) is defined as a reduction of score >2 or a >50% reduction of the 
pre-treatment pain score. Response is classified as positive if no increase in analgesic use 
was evident. 
Stable disease (SD) is defined by an unaltered pain score 
 Progressive disease (PD) by an increase in the score >2 or a >50% increase in the pre-
treatment pain score. 
TOXICITY  ASSESSMENT:
Radiotherapy Oocology   Group ( RTOG) Toxicity Criteria .
Upper GI – RTOG acute morbidity scoring criteria
  
Grade                                       Change
0 No change
1
Anorexia with 5% weight loss from base line. Nausea,
abdominal pain not requiring medication.
2
Anorexia with 15% weight loss from base line. Nausea,
abdominal pain,vomiting  requiring medication.
3
Anorexia with >15% weight loss from base line requiring 
NG tube or parenteral support. Severe abdominal pain
despite medication. Haematemesis, melena or abdominal distention
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4Ileus, sub-acute obstruction, perforation, GIT bleeding requiring
transfusion. Abdominal pain requiring tube decompression or
bowel diversion.
                                                      
Lower GI including pelvis - RTOG acute morbidity scoring criteria
Grade Change
0 No change
1
Increased frequency or change in bowel habits, rectal
discomfort not requiring medication.
2
Diarrhea requiring para-sympatholytic drug. Mucous
discharge, rectal / abdominal pain requiring medication.
3
Diarrhea requiring paraenteral support, mucous or bloody
discharge requiring sanitary pads.
4
Acute /  subacute obstruction, fistulae or perforation, GIT bleeding
Requiring transfusion. Abdominal pain, tenesmus requiring tube
decompression or bowel diversion.
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RESULTS
              Out of the 1802 Cancer patients treated between July- 2008 and June- 2009 in  
our Radio therapy dept, 85 (4.7%) presented with bone metastases. A total of 60 patients 
with single and multiple bone metastases who met the eligibility criteria entered into this  
study at  the time they developed their  first  painful  bone metastases.  Any subsequent 
metastases and  its treatment was not included in the study and every effort was made to 
distinguish the pain that first occurred from that of any subsequent metastatic site, even in 
the cases of pain recurrence at the original site in the presence of painful second or any 
other additional metastatic bone site.
PATIENTS CHARACTERISTIC
1. NUMBER OF CASES
                   Arms                   Number of cases
 6Gy  ARM (TRIAL ARM)                               30
 8Gy  ARM ( CONTROL ARM)                               30
2.AGE DISTRIBUTION
                  In this study in trial arm (6Gy) we enrolled patients between 21-70 years of 
age.  The median age of the patients in 6Gy arm was 53 years and most (40%) of the 
patients were in the 5th decade of life. In control arm (8Gy) we enrolled patients between 
31-70 years of age.  The median age of the patients in 6Gy arm was 55 years and most  
(46%) of the patients were in the 5th decade of life.
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3. SEX DISTRIBUTION
               In both arms female patients are more than male patients.  Male : female ratio is  
1:1.7  in 6Gy arm  and  1:2.3  in 8Gy arm.
4.PRIMARY TUMOR SITES
               In  this study  bone metastases  predominatly from  carcinoma breast( >50%) 
and  lung cancer(>26%)  in both  arms.
            SITE           6Gy Arm            8Gy Arm
         BREAST           17 (57%)            16 (54%)
         LUNG            8 (26%)              9 (30%)
        PROSTATE            2  (7%)            3 (10%)
        PNET            2 (7%)            1(3%)
        KIDNEY            1 (3%)            --
        THYROID            --            1(3%)
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    Age Group(Years)       6Gy Arm            8Gy Arm
              21 - 30            1(3%)                -
              31 - 40            3(10%)            3(10%)
             41 - 50            6(20%)            7(23%)
             51 - 60            12(40%)            14(46%)
              61 - 70            8 (26%)            6(20%)
            SEX        6Gy Arm        8Gy Arm
          Male         11(37%)           9 (30%)
          Female         19(63%)           21(70%)
 5.METASTATIC BONE SITES
SITE 6Gy ARM 8Gy ARM
      CERVICAL SPINE 1 1
      DORSAL SPINE 17 18
      L-S SPINE 13 12
      PELVIS/HIP 1 3
      FEMUR 4 3
      HUMERUS 3 2
      METATARSAL 1 -
      STERNUM 1 -
In both study groups dorsal spine and lumbo - scaral spine are more commonly involved.
 6.INITIAL PAIN SCORE
PAIN SCORE 6Gy ARM 8Gy ARM
          MILD 5 (17%) 5(17%)
          MODERATE 13 (43%) 11(37%)
          SEVERE 12 (40%) 14(46%)
               In this study we included 13% of the patients had mild pain and 83% of patients 
in each group had moderate to severe pain, a finding consistent with the reports in the 
literature.
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7. INITIAL ANALGESIC REQUIRMENT
ANALGESIC DRUGS 6Gy ARM 8Gy ARM
  ANALGESIC (NSAID) 5 (17%) 4(13%)
  MILD NARCOTIC 23 (76%) 24 (80%)
  STRONG NARCOTIC 2 (7%) 2 (7%)
                  In this study the trial (6Gy)  arm 17% of patients on NSAID drugs, 76% of  
patients  on  mild  narcotic  drugs  i.e.  Tramadol  and  7%  on  strong  narcotic  drug  i.e. 
Morphine. In control (8Gy) arm 13% of patients on NSAID drugs, 80% of patients on 
mild narcotic drugs i.e. Tramadol and 7% on strong narcotic drug i.e. Morphine before 
strating the radiotherapy treatment.
                 There were no differences among the two   treatment groups in any of these  
characteristics.  No  difference  was  found  among the  two  treatment  groups  regarding 
initial pain score and the use of analgesics.
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8.TREATMENT FIELDS
NO. OF FIELDS 6Gy ARM 8Gy ARM
ONE 12(40%) 10(33%)
TWO 15(50%) 17(67%)
THREE 3(10%) 3(10%)
                In trial arm ( 6Gy) 50% of patients were treated with two fields and 40% with 
one fields. In control arm 67% of patients were treated with two fields and 33% with one 
fields. 10% of the patients were treated with three fields in both arms.
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 INITIAL ANALGESIC REQUIRMENT
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CLINICAL RESPONSE ASSESSMENT
                 Although our initial aim was to monitor treatment response for at least 24  
weeks and as long as possible thereafter, due to the fact that many patients died after 8 
weeks from their RT, we used response that occurred up to 8 weeks post-RT to evaluate  
60
treatment response, since all 60 patients survived that period and fully returned for study 
evaluation.
9.RESPONSE ASSESSMENT OF 6Gy ARM
RESPONSE WEEK 1 WEEK2 WEEK 4 WEEK 8
PARTIAL RESPONSE 1 2 4 9 (30%)
COMPLETE RESPONSE 0 3 8 13 (43.3%)
OVER ALL RESPONSE 1 5 12 22 (73.3%)
The analysis of clinical response at the end of the 8th week revealed the following:
a. PARTIAL CLINICAL RESPONSE – In this  arm a total of 9 patients  attained 
partial clinical response  i.e. 30% of all  trial patients.
b. COMPLETE CLINICAL RESPONSE – A total of  13  patients attained complete 
clinical response  i.e. 43.3% of all  trial patients.
c. OVER ALL CLINICAL RESPONSE -- In this arm a total of 22 patients attained 
overall clinical response  i.e.73.3% of all  trial patients.
61
10.RESPONSE ASSESSMENT OF 8Gy ARM
RESPONSE WEEK 1 WEEK 2 WEEK 4 WEEK 8
PARTIAL RESPONSE 1 3 4 9 (30%)
COMPLETE RESPONSE 0 3 9 14 (46.6%)
OVER ALL RESPONSE 1 6 13 23 (76.6%)
The analysis of clinical response at the end of the 8th week revealed the following:
a. PARTIAL CLINICAL RESPONSE – In this  arm a total of 9 patients  attained 
partial clinical response  i.e. 30% of all  trial patients.
b. COMPLETE CLINICAL RESPONSE – A total of  14  patients attained complete 
clinical response  i.e. 46.6% of all  trial patients.
c. OVER ALL CLINICAL RESPONSE -- In this arm a total of 2 patients attained 
overall clinical response  i.e.76.6% of all  trial patients.
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            Although we scored response at 12 and 24 weeks post-RT, we found it impossible 
to present meaningfully. Both CR and overall response rates rose sharply at 12 (and 24) 
weeks post-RT, and were 95–100% for overall response rates at 24 weeks post-RT which 
were due to the death of many patients after 8 weeks post-RT, especially non-responders.
DURATION OF RESPONSE IN RESPONDERS:
              We analyzed mean duration of response in responders in both treatment groups.  
We found that  the trial arm(6Gy) patients have 21.3 mean weeks of pain free periods.  
The control arm(8Gy) patients have 25.1 mean weeks of pain free periods.
11. DURATION OF RESPONSE IN RESPONDERS
ARMS N MEAN(WEEKS) SD
P value
6Gy ARM 22 21.3 8.6
0.188Gy ARM 23 25.1 10.2
             No difference was found between the two treatment groups regarding the  
duration of response in responders  whose mean values ranged from 21 to 25 weeks.
TIME TO THE FIRST OCCURRENCE OF ANY PAIN RELIEF:
            We also analyzed the first occurrence of any pain relief in responders in both  
treatment groups.  We found that  the trial arm(6Gy) patients have  any pain relief at 4.36 
weeks( mean). The control arm (8Gy) patients have any pain relief at 4.22 mean weeks .
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12.TIME TO THE FIRST OCCURRENCE OF ANY PAIN RELIEF
ARMS N MEAN(WEEKS) SD P value
6Gy ARM 22 4.36 1.9
0.808Gy ARM 23 4.22 1.9
               However, when using time to the first occurrence of any pain relief as an 
endpoint, no difference between  6Gy arm and 8Gy arm.
INFLUENCE OF HISTOLOGY ON RESPONSE
                    In order to investigate influence of histology on response, we evaluated 
response to treatment according to various histologies. There was no difference between 
the various groups of patients,  except that patients having tumors considered such as 
breast,  and prostate,  tended  to  have  higher  overall  response  rates  than  those  having 
tumors of the lung, kidney, or PNET, but the difference was not significant.  Due to a 
small patient numbers in different subgroups compared, any further analysis would be 
meaningless.
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13.OVERALL RESPONSE AT 8 WEEKS ACCORDING TO HISTOLOGY 
PRIMARY TUMOR SITES
SITE BOTH ARMS 6Gy ARM 8Gy ARM
BREAST 26 /33 (78%) 13 /17 (76%) 13/ I6 (81%)
LUNG 11 /17 (64.7%) 5 /8 (62.5%) 6/9 (66.6%)
PROSTATE 4 /5 (80%) 2/2 (100%) 2/ 3 (66.6%)
PNET 2 /3 (66.6%) 1 /2 (50%) 1 /1 (100%)
KIDNEY 1 /1 (100%) 1 /1 (100%) --
THYROID 1/1 (100%) - 1 /1 (100%)
INFLUENCE OF METASTATIC SITE ON RESPONSE
          We also analyzed the influence of metastatic bone site in overall response rate at 8  
weeks.  It revealed metastatic site had no influence on the overall response rate up to 8 
weeks post-RT   and patients with different metastatic sites treated did not have different 
response rates.
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14.OVERALL  RESPONSE  AT  8  WEEKS  ACCORDING  TO METASTATIC 
BONE SITES
SITE BOTH ARMS 6Gy ARM 8Gy ARM
CERVICAL SPINE 2 /2 (100%) 1 /1 (100%) 1 /1 (100%)
DORSAL SPINE 27 /35 (77%) 13 /17 (76.4%) 14 /18 (77.7%)
L-S SPINE 18 /25 (72%) 9/ 13 (69%) 9 /12 (75%)
PELVIS / HIP 3 /4 (75%) 1/1 (100%) 2/3 (66.6%)
FEMUR 5/7 (71.4%) 3 /4 (75%) 2/3 (66.6%)
HUMERUS 4/5 (80%) 2/3 (66.6%) 2/2 (100%)
METATARSAL 1 /1 (100%) 1/1 (100%) -
STERNUM 1/1 (100%) 1 /1 (100%) -
RETREATMENT
             In trial arm two patient  one with PNET and  another with lung cancer were 
retreated  with 6Gy at the end of 9 week, who were non responders after  first treatment. 
In control arm two patient  one with breast and  another with lung cancer were retreated 
with 8 Gy at the end of 9 week, who were non responders after  first treatment. The 
metastatic site was in dorsal spine in all four patients.
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            There was no difference in incidence of retreatment by RT during the study  
period  among the  two treatment  groups,  occurring  in  2/30  (6.6%),  and 2/30 (6.6%) 
patients in the, 6Gy arm and 8Gy arm. respectively (p= 0.5 ). 
TOXICITY
               No pathological fractures or spinal cord compressions were seen in this patient 
population during the 8 weeks post-RT.  Nausea and vomiting grade 1 and 2 occurred , 
in 5/30 (16.6%) patients in 6Gy arm, and in 6/30 (20%) patients in 8Gy arm ( p =0.38).  
Diarrhea grade 1 and 2 occurred   in 3/30 (10%) patients in 6Gy arm and in 5/30 (16.6%) 
patients in 8Gy arm ( p =0.21).  There were no other acute gastrointestinal toxicity. No 
effect of field size on the incidence of toxicity was found.
DURATION OF RESPONSE IN RESPONDERS
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DISCUSSION
             Bone metastases  are observed in approximately 50% of patients with cancer. 
Metastatic disease to the bone is a common cause of pain and other significant symptoms 
that are detrimental to quality of life.  Radiotherapy is considered as the treatment of 
choice. Its main aim is relief of bone pain, prevention of pathological fracture as well as 
its healing, with anticipated effect upon improving mobility, function, and  quality of 
life.                 
             Our primary aim was to attempt to define the optimal lowest single fraction RT 
in painful bone metastatic patient population. 
             Target  cells  of radiotherapy in painful bone metastases are inflammatory cells 
and  osteoclasts.  By giving very low single dose i.e.  4Gy  shown to cause pain relif, 
without showing any   tumour  shrinkage. Here  obvious target cells are the inflammatory 
cells that are largely present in the bone metastases micro-environment. Reduction by 
ionizing  radiation  of  the  inflammatory  cells  inhibits  the  release  of  chemical  pain 
mediators  and  is  probably  responsible  for  the  rapid  reaction  seen  in  some  patients 
(Mercadante, 1997).
             
                  Other target cells are the osteoclasts.  Osteoclastic activity is an early and  
important  response  to  tumour  cell  invasion.  Recently  it  has  been  demonstrated  that 
urinary markers of bone resorption (and thus osteoclastic activity) and pain relief after 
radiation treatment were correlated (Hoskin et al., 2000).
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              Doses of  5 Gy  given to metatarsal bones of embryonic mice resulted in a 
selective elimination of the precursor cells for osteoclast formation (Scheven et al., 1986). 
A  clear  dose-response  relationship  between  the  dose  of  ionizing  radiation  and  the 
decrease in osteoclast number in vitro was observed (Tsay et al., 1995). The calculated 
life span of the osteoclast in this study was 9 to 10 days. In a further investigation by the 
same group (Tsay et al.,  1999)  they showed that in the first  weeks after exposure to 
moderate doses of ionizing radiation the number of osteoclasts did not diminish.
                 
                 Other studies have shown that the influx of osteoclast precursor cells in vivo is 
effectively suppressed by ionizing radiation (Comas, 1970). The resorbing activity of the 
osteoclast is less radiosensitive but can be inhibited, in a dose dependent way, by a dose 
of  at  least  5  Gy,  as  was established by morphometric  and biochemical methods in  a 
mouse embryo model (Scheven et al., 1985). 
                Here we studied two higher (6 and 8 Gy, respectively) single fractions 
radiotherapy to   painful bone metastases.  Results of this study show that two higher  
single fractions   achieved better results in terms of CR, and significantly better in terms 
of overall response rates. 
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CLINICAL RESPONSE ASSESSMENT
The analysis of clinical response at the end of the 8th week revealed the following
COMPLETE CLINICAL RESPONSE : 
                A total of  13/30  patients attained complete clinical response  i.e. 43.3% of all  
trial patients. In  control arm 14 / 30 patients attained complete clinical response  i.e. 
46.6%.  The  p-value  is  0.5   significant,  thereby  indicates   both  study groups have 
equivalent complete response.
CR RATE
ARM Week 1 Week 2 Week 4 Week 8
6 Gy ARM 0 3/30 8/30 13/30 (43.3%)
8Gy ARM 0 3/30 9/30 14/30 (46.6%)
P-value 0.5 0.5 0.44 0.5
PARTIAL CLINICAL RESPONSE:
                A total of  9/30  patients attained parital clinical response  i.e. 30% of all  trial  
patients. In  control arm 9 / 30 patients attained partial clinical response  i.e. 30%.  
The  p-value is 0.5   significant, thereby  indicates  both study groups have equivalent 
partial response.
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0.5
PR RATE
ARM Week 1 Week 2 Week 4 Week 8
6 Gy ARM 1/30 2/30 3/30 9/30 (30%)
8Gy ARM 1/30 3/30 4/30 9/30 (30%)
P-value 0.5 0.45 0.44
OVERALL RESPONSE RATE
             A total of  22/30  patients attained clinical response  i.e.73. 3% in trial patients. In 
control arm 23 / 30 patients attained  clinical response  i.e. 76.6%. The p-value 0.40  in 
overall response rate  is significant.
ARM Week 1 Week 2 Week 4 Week 8
6 Gy ARM 1/30 5/30 11/30 22/30 (73.3%)
8Gy ARM 1/30 6/30 13/30 23/30 (76.6%)
P-value 0.5 0.44 0.25 0.40
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DURATION OF RESPONSE IN RESPONDERS:
              We analyzed mean duration of response in responders in both treatment groups.  
We found that  the trial arm(6Gy) patients have 21.3 mean weeks of pain free periods.  
The  control  arm(8Gy)  patients  have  25.1  mean  weeks  of  pain  free  periods. 
The p-value 0.18  is significant.
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TIME TO THE FIRST OCCURRENCE OF ANY PAIN RELIEF:
             We also analyzed the first occurrence of any pain relief in responders in both  
treatment groups.  We found that  the trial arm(6Gy) patients have  any pain relief at 4.36 
weeks( mean). The control arm(8Gy) patients have any pain relief at 4.22 mean weeks.  
The p-value 0.8  is significant.
RETREATMENT
             The retreatment rate were 2/30 (6.6%), and 2/30 (6.6%) patients in the, 6Gy arm 
and 8Gy arm. respectively (p= 0.5 ).
TOXICITY
             Nausea and vomiting grade 1 and 2 occurred, in 5/30 (16.6%) patients in 6Gy 
arm, and in 6/30 (20%) patients in 8Gy arm ( p =0.38).  Diarrhea grade 1 and 2 occurred 
in 3/30 (10%) patients in 6Gy arm and in 5/30 (16.6%) patients in 8Gy arm ( p =0.21).
            So, the speed of onset of pain relief,   response duration , retreatment rate, and  
toxicity there is no difference between 6Gy arm and 8Gy arm . Also we could not find 
any influence of histology or metastatic site on pain relief between the two treatment 
groups, which may have some implications for future studies.
ANALYSIS OF SINGLE FRACTION 6Gy RADIOTHERAPY PROTOCOLS
               The radiation dose was chosen taking into account the various protocols tried 
out by the various studies like Barak et al  12, Uppelschoten et al  41, Jermic et al  42, and 
Metin Guden et al 43.
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AUTHOR(REF) YEAR RT DOSE(Gy) OVER ALL 
RESPONSE 
RATE(%)
Barak et al. 1987 6 71
Uppelschoten et al. 1995 6 88
Jeremic et al. 1998 4 59
6 73
8 78
Metin Guden et al. 2002 6 88.7
CURRENT STUDY 6
8
73.3
76.6
              From this table overall response rate for single fraction 6Gy radiotherapy was  
ranges from 71 – 88%.  The Uppelschoten et al study and  Metin Guden et al. study gave
Highest response rate i.e. 88%. Our current study gives compareable overall response rate 
for 6Gy and 8Gy single fraction radiotherapy i.e. 73.3% and 76.6%.
                Since single fraction RT of 6 Gy did not produce results inferior to that  
obtained  with  8  Gy,  further  studies  are  needed  to  get  more  informations  regarding 
optimal single fraction RT in the treatment of painful bone metastases.
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CONCLUSION
                  The following conclusions can been drawn from this prospective trial which 
compared  6Gy single  fraction radiotherapy with already proven 8Gy single  fraction 
radiotherapy in the treatment of painful bone metastases.
                  The 6Gy single fraction radiotherapy produces similar , time to the first 
occurrence of any pain relief, duration of response in responders, complete response rate, 
overall response rate, retreatment rate and toxicity with 8Gy single fraction radiotherapy 
in the treatment of painful bone metastases.
                  
                  We conclude that single fraction 6Gy radiotherapy is good option in 
palliation of painful bone metastases.  
                  The impact of this single fraction   on long term survival as well as the long  
term morbidity are to be analyzed in future with larger sample size. This task would 
certainly not be easy to achieve, unless performed in a prospective randomized multi-
institutional cooperative group trial that will enable sufficient number of patients for any 
analysis needed with that aim.  Having a world  wide  problem of bone metastases in 
mind, extremely big population of cancer patients would be eligible for the study of that 
type.  It may now be the time for undertaking such trial that may help get some answers 
regarding  “optimum low dose  single  fraction RT” in the  treatment  of  painful  bone 
metastases.
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